A vaccine used to treat prostate cancer that has spread to other parts of the body. It is used in patients who have few or no symptoms and whose cancer is castration resistant (has not responded to treatments that lower testosterone levels). Sipuleucel-T is made from a patient’s immune cells that have been treated in the laboratory with GM-CSF (a type of growth factor) and a protein found on prostate cancer cells. Sipuleucel-T may help the immune system kill prostate cancer cells. It is a type of cellular adoptive immunotherapy. Also called APC8015 and Provenge.